Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial
Exposure following subcutaneous belimumab administration in pediatric patients is consistent with approved usage; these findings, along with consistent safety and efficacy data, support subcutaneous belimumab use for pediatric patients with SLE.
Authors
- Christel Wilkinson
- Deepak Assudani
- Hermine I. Brunner (ORCID: https://orcid.org/0000-0001-9478-2987)
- Yuichi Yamasaki (ORCID: https://orcid.org/0000-0003-1765-1494)
- Jordi Antón (ORCID: https://orcid.org/0000-0002-8792-4219)
- Rebecca Marino
- Masaaki Mori (ORCID: https://orcid.org/0000-0003-2130-4866)
- Kirsten Minden (ORCID: https://orcid.org/0000-0003-2775-0111)
- André van Maurik (ORCID: https://orcid.org/0000-0002-1954-0141)
- Gerd Horneff (ORCID: https://orcid.org/0000-0001-5491-7832)
- Richard Dimelow (ORCID: https://orcid.org/0000-0003-1246-5705)
- Josephine C Ocran-Appiah (ORCID: https://orcid.org/0000-0002-8413-131X)
- Sylvia Kamphuis
- Inmaculada Calvo‐Penadés
Institutions
- North Carolina Central University (US)
- Cincinnati Children's Hospital Medical Center (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- St. Marianna University School of Medicine (JP)
- Age UK (GB)
- Erasmus MC (NL)
- Hospital Universitari i Politècnic La Fe (ES)
- GlaxoSmithKline (United States) (US)
- Kagoshima University Hospital (JP)
- NSK (United Kingdom) (GB)
- Asklepios Klinik Sankt Augustin (DE)
- University Hospital Cologne (DE)
- Institute of Science Tokyo (JP)
- Universitat de Barcelona (ES)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Arthritis Care & Research
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1002/acr.25700
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00